Notice Regarding Securities Valuation Loss for the First Quarter of the Fiscal Year Ending September 2026

Overview of Securities Valuation Loss

In the first quarter of the fiscal year ending September 2026 (October 1, 2025 to December 31, 2025), Fuji Pharmaceutical Co., Ltd. recorded a securities valuation loss of JPY 2,457 million due to a significant decline in the market value of other securities held by the company. The primary cause was a drop in the share price of Alvotech Holding S.A. (listed on NASDAQ), a global licensor in the biosimilar business. The valuation method used is the wash sale method; therefore, the valuation loss may fluctuate depending on stock prices at future quarterly and fiscal year-ends.

Outlook

Regarding the impact on consolidated earnings for the cumulative second quarter and the full fiscal year ending September 2026, please refer to the 'Notice of Revision of Earnings Forecast' published on the same day. The fiscal year-end is September 30.